Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancerCompanies: Roche HoldingBasel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. This approval marks the twelfth indication for Tecentriq in the US.
- From Phase III Trials to Commercialization Partnerships, MindRank's AI Drug Development Value Comes into FocusHong Kong, Oct 9, 2026 - As AI Drug Development Approaches Commercialization, MindRank Marks a Key Business Milestone How much value can AI create in the discovery and development of new medicines' For investors following the sector, the answer lies in tangible progress in drug development and business execution. A platform’s ability to consistently generate drug candidates, advance lead assets through clinical development and secure recognition from industry partners provides an important basis for assessing an AI drug developer’s growth potential. The recently announced commercialization partnership by MindRank AI Ltd. (MindRank, hereinafter “MindRank”) offers a new window into this question. On September 28, 2026, MindRank announced an exclusive commercialization partnership with 3SBio (01530.HK) subsidiaries Sunshine Mandi and Wansheng Pharmaceutical for MDR-001, its internally developed, AI-designed oral small-molecule GLP-1 receptor agonist. Covering mainland China, Hong Kong and Macau, the agreement carries a potential total transaction value of up to RMB1.75 billion, alongside a substantial share of sales revenue. MDR-001 is currently undergoing a pivotal Phase III clinical trial in China in adults with obesity or overweight. For MindRank, a clinical-stage AI-native drug discovery and development technology company, the partnership further connects drug development with commercialization planning. It lays the groundwork for marketing its lead asset following potential approval and establishes a clearer pathway for translating AI-driven research into commercial value. As its lead asset advances through pivotal clinical development, MindRank has begun preparing for post-approval marketing and channel coverage, extending the product’s development pathway into commercialization. Under the agreement, Sunshine Mandi and Wansheng Pharmaceutical will provide exclusive, comprehensive services and distribution across all channels following MDR-001’s launch. MindRank will retain all rights, title and interests in the product’s intellectual property and remain responsible for clinical development, regulatory submissions, manufacturing and supply. The transaction includes up to RMB150 million in payments for collaboration rights, up to RMB1.6 billion in royalty payments upon the fulfillment of agreed conditions, and a substantial share of sales revenue. From a business-model perspective, the agreement establishes a clear division of responsibilities. MindRank will continue investing in research and product development, while its partners will provide exclusive, comprehensive services and distribution across all channels within the agreed territories following regulatory approval and launch. In an industry that requires sustained investment, this collaboration could help MindRank retain its core asset rights while drawing on its partners’ commercial capabilities to support launch preparations and focus its own resources on strengthening its core capabilities. The partners’ willingness to make commercialization arrangements for an investigational drug also provides a new reference point for assessing its potential industry value. Clinical data address whether a product merits further development, while commercial partnerships indicate whether industry participants are willing to take part in its subsequent development. Together, these elements make MindRank’s growth story more tangible. A Lead Asset in Phase III Provides a Clearer Basis for Assessing AI-Driven R&D Capabilities The core asset underpinning the partnership is MDR-001, which continues to advance through development. In February 2026, MindRank announced that the first participant had been dosed in MOBILE, its Phase III clinical trial of MDR-001. According to the company, the multicenter, randomized, double-blind, placebo-controlled study plans to enroll approximately 750 participants across around 50 clinical centers in China to further evaluate the product’s long-term efficacy and safety. This means the evidence available to assess MindRank’s AI-driven R&D capabilities now extends to larger-scale, late-stage clinical research. For investors, the lead asset’s entry into Phase III sharpens the focus on several key questions: whether long-term efficacy can be further validated, whether safety and tolerability findings can be sustained, and whether the product can establish clinically meaningful competitive advantages. Previously disclosed Phase IIb findings supported further development. In the study, which enrolled 317 adults with obesity or overweight, participants in the MDR-001 dose groups achieved mean reductions in body weight from baseline of 8.2% to 10.3% after 24 weeks, compared with 2.5% in the placebo group. The rate of treatment discontinuation due to treatment-emergent adverse events was 0.8%. Common adverse events were primarily gastrointestinal and mostly mild to moderate. These findings remain subject to further validation in subsequent studies. For weight-management medicines, product value depends on a combination of weight-loss efficacy, long-term safety, tolerability and ease of use. Compared with the injectable peptide-based GLP-1 medicines that currently dominate the market, MDR-001’s oral small-molecule formulation can significantly improve medication adherence, while its large-scale manufacturing costs are substantially lower than those of peptide-based medicines, offering considerable market potential and commercial value. These attributes provide a promising direction for its future product positioning, although translating them into a competitive advantage will require continued accumulation of clinical evidence. Beyond progress in product development, R&D efficiency is another important lens through which to assess MindRank. According to the company, MDR-001 progressed from project initiation to preclinical candidate (PCC) nomination in just eight months, during which approximately 80 small molecules were synthesized. Its investigational new drug (IND) application was cleared in the United States within 19 months of project initiation and MDR-001 advanced to Phase III in China in approximately 4.5 years. In its July 2026 financing announcement, the company further disclosed that cumulative direct R&D investment in the program, from initiation through the start of Phase III in China, totaled approximately US$23 million. These timelines and investment figures provide a more concrete basis for understanding how MindRank organizes drug discovery and development. For drug developers, development timelines and funding requirements directly affect how many programs they can advance, how long they can sustain development and how they allocate resources to subsequent work. AI’s commercial significance must also be assessed within these real-world R&D constraints. As a flagship application of MindRank’s AI-driven drug discovery and development system, MDR-001 offers a traceable development pathway: from molecular design to clinical research and, subsequently, commercialization partnerships. The platform’s capabilities are beginning to be tested through tangible business outcomes. This provides capital markets with a more useful basis for understanding the company’s technology value than descriptions of algorithms or model parameters alone. Beyond the Lead Asset, Long-Term Growth Depends on Sustained Platform Output MDR-001 is the central focus of MindRank’s business progress at this stage, while the company’s long-term growth potential also depends on its ability to continue developing new drug assets. According to the MindRank, its end-to-end AI drug development engine, MAP (Molecule Arts Platform), integrates biology, chemistry, computation, experimental validation and clinical learning into a unified drug discovery and development system. In July 2026, the company announced that it had completed a cumulative US$52 million Series B financing in stages, with proceeds earmarked for further platform development and the advancement of its clinical and preclinical pipeline. In September 2026, the company formally launched Intera (Intelligence Era), its life-sciences foundation model system, and released a technical report on InteraFold-Chem, the first model in the InteraFold series. From an operating perspective, platform development and pipeline advancement have the potential to reinforce each other. R&D programs bring real-world problems and experimental feedback to the platform, while platform iterations support the discovery and optimization of subsequent programs. Ultimately, the platform’s value must be reflected in sustained output: its ability to advance more molecules with development potential across different targets and disease areas, gradually building a business supported by multiple assets. MindRank has already expanded beyond metabolic diseases. In March 2025, the company disclosed that MRANK-106, an oral dual inhibitor of WEE1 and YES1, had received IND approval in the U.S. in oncology. This development provides another case through which to assess the applicability of its AI platform across different R&D areas, although the product’s potential remains subject to subsequent clinical validation. In earlier-stage research, the company disclosed in April 2026 that a collaborative study on drug discovery for Alzheimer’s disease, conducted by MindRank, the University of Macau and Imperial College London, had been published in Nature Biomedical Engineering. The work combined AI screening with experimental validation to identify small molecules meriting further investigation, demonstrating the company’s research capabilities and exploration at the forefront of drug discovery for complex diseases. These programs are at different stages, and their contributions to the company’s value need to be assessed separately. MDR-001 remains the main focus of current clinical development and commercialization preparations, while other pipeline programs and research support the platform’s broader applicability and long-term project portfolio. As more programs deliver verifiable progress, outside observers will be better positioned to assess whether the company can consistently replicate its R&D capabilities. Viewed through this lens, the recent commercialization partnership offers an opportunity to reassess MindRank. Its lead asset has entered pivotal clinical development, partners are participating in commercialization preparations at an early stage, financing supports continued R&D, and its presence across multiple areas preserves opportunities for future growth. These interconnected developments make the company’s development trajectory easier for capital markets to understand. MDR-001 remains in clinical development and has not yet received marketing approval. Its future value realization depends on clinical results, regulatory approval and commercial execution. Nevertheless, the business progress achieved to date provides a more concrete basis for assessing MindRank. For investors following opportunities at the intersection of AI and innovative medicines, the central question worth tracking is whether the company can progressively translate its established R&D capabilities into more verifiable drug assets and commercial outcomes.
- 從Ⅲ期臨床到商業化合作 德睿智藥的AI製藥價值逐步顯現香港, 2026年10月9日 - AI製藥進入準商業化階段，德睿智藥迎來關鍵業務進展 AI究竟能為新藥研發創造多大價值？對於關注這一領域的投資人而言，答案需要在具體的藥物和業務進展中尋找。研發平台能否持續產出候選藥物，核心產品能否取得臨床進展，以及研發成果能否獲得產業合作夥伴認可，共同構成了判斷一家AI製藥企業成長潛力的重要依據。 杭州德睿智藥科技有限公司（MindRank，以下簡稱「德睿智藥」）近期披露的商業化合作，為觀察這一問題提供了新的窗口。 2026年9月28日，德睿智藥宣布，與三生製藥（01530.HK）旗下三生蔓迪及萬晟醫藥，就其自主研發的AI設計口服小分子GLP-1受體激動劑MDR-001達成獨家商業化合作，覆蓋中國內地、香港及澳門，潛在總交易金額最高可達人民幣17.5億元，並可獲高比例銷售分成。該產品目前正在中國開展針對成人肥胖或超重人群的Ⅲ期關鍵臨床研究。 對於德睿智藥這家臨床階段AI Native新藥研發科技公司而言，此次合作進一步銜接了新藥研發與商業化布局，為核心產品未來獲批後的市場推廣奠定基礎，也讓AI驅動的研發成果向商業價值轉化的路徑更加清晰。在核心產品推進關鍵臨床研究的同時，德睿智藥開始為未來獲批後的市場推廣和渠道覆蓋作準備，使產品開發路徑進一步延伸至商業化環節。 根據協議安排，三生蔓迪及萬晟醫藥將承接MDR-001上市後的全渠道獨家綜合與經銷服務；德睿智藥保留產品知識產權的全部權利、權屬和權益，繼續負責臨床開發、註冊申報與生產供應。交易包括最高1.5億元合作權付款，以及達到約定條件後最高16億元的特許權使用付款，以及高比例銷售分成。 從業務模式來看，這一安排體現出明確的分工：德睿智藥持續投入研發及產品開發，合作方負責約定區域內、產品獲批上市後的全渠道獨家綜合與經銷服務。對於需要長期投入的創新藥業務，這種協同有望幫助德睿智藥在保留核心資產權益的同時，藉助合作方的商業運營能力銜接上市準備，並將自身資源集中於核心能力建設。 合作方願意圍繞一款在研產品作出商業化安排，也為外界評估其潛在產業價值提供了新的參考。臨床數據回答產品是否值得繼續開發，商業合作則進一步回答產業夥伴是否願意參與其後續發展。兩者相互銜接，使德睿智藥的成長邏輯更加具體。 核心產品邁入Ⅲ期，讓AI研發能力有了更清晰的觀察依據 支撐此次合作的核心資產，是持續取得研發進展的MDR-001。 2026年2月，德睿智藥宣布，MDR-001的Ⅲ期臨床研究MOBILE完成首例受試者給藥。根據公司披露，該研究採用多中心、隨機、雙盲、安慰劑對照設計，計劃在中國約50家臨床中心納入約750名受試者，進一步評價產品的長期有效性與安全性。 這意味著，評價德睿智藥AI研發能力的依據，已經延伸至較大規模的後期臨床研究。對於投資人而言，核心管線進入Ⅲ期，使後續觀察重點更加明確：長期療效能否得到進一步驗證，安全性和耐受性表現能否延續，以及產品能否形成具有實際臨床意義的競爭力。 此前披露的Ⅱb期研究為後續開發提供了支持。在這項納入317名成人肥胖或超重受試者的研究中，MDR-001各劑量組治療24周後平均體重較基線下降8.2%至10.3%，安慰劑組下降2.5%；因治療期間出現的不良事件而終止治療的比例為0.8%。研究中常見的不良事件主要為胃腸道症狀，多為輕至中度。上述結果仍需通過後續研究進一步驗證。 對於體重管理藥物，產品價值需要綜合考慮減重效果、長期安全性、耐受性和使用便利性。相較於當前主流的注射類多肽GLP-1藥物，MDR-001作為口服小分子製劑，可顯著提升患者用藥依從性，規模化製備成本遠低於多肽類藥物，將極具市場潛力和商業價值。這為其後續產品定位提供了一個值得關注的方向；而能否將這一特點轉化為實際競爭優勢，則需要持續積累臨床證據。 在產品進展之外，研發效率也是理解德睿智藥的重要角度。 據公司披露，MDR-001從項目啟動到確定臨床前候選化合物（PCC）僅用8個月，期間實際合成約80個小分子；從項目啟動至獲得美國新藥臨床試驗許可用時19個月，約4.5年推進至中國Ⅲ期臨床。公司2026年7月發布的融資消息進一步披露，從立項至中國Ⅲ期臨床啟動，項目累計直接研發投入約2,300萬美元。 這些時間與投入數據，為理解德睿智藥如何組織新藥研發提供了更具體的討論基礎。對於新藥研發企業而言，研發周期與資金投入直接關係到企業能夠推進多少項目、承擔多長時間的開發，以及如何安排後續資源。AI的商業意義，也需要放在這些真實的研發約束中衡量。 作為德睿智藥AI新藥研發體系的核心實踐，MDR-001已經提供了一條可追蹤的開發路徑：從分子設計到臨床研究，再到商業化合作，平台能力開始通過實際業務成果接受檢驗。這比單純介紹算法或模型參數，更有助於資本市場理解公司的技術價值。 從核心管線到平台延展，長期成長空間取決於持續產出能力 MDR-001決定了德睿智藥現階段最重要的業務看點，而公司的長期成長空間，還取決於能否持續開發出新的藥物資產。 德睿智藥披露的全鏈路AI製藥引擎MAP（Molecule Arts Platform），將生物學、化學、計算、實驗驗證與臨床學習納入統一新藥研發體系。2026年7月，公司宣布分階段完成累計5,200萬美元B輪融資，資金將用於繼續推進平台建設及臨床、臨床前管線開發。2026年9月，公司正式發布生命科學基座模型體系Intera (Intelligence Era)，並公布InteraFold系列首個模型InteraFold-Chem技術報告。 從經營角度看，平台建設與管線推進具有相互促進的潛力：研發項目為平台帶來真實問題和實驗反饋，平台迭代則服務於後續項目的發現與優化。其價值最終需要體現為持續產出能力——能否在不同靶點和疾病領域推進更多具備開發價值的分子，並逐步形成多項資產支撐的業務結構。 德睿智藥已在代謝疾病之外展開布局。公司於2025年3月披露，口服WEE1及YES1雙靶點抑制劑MRANK-106獲得美國FDA的新藥臨床試驗許可，擬用於開展腫瘤領域的臨床研究。這一進展為觀察其AI平台在不同研發方向上的適用性提供了另一個案例，相關產品潛力仍需後續臨床驗證。 在更早期的研究方面，公司於2026年4月披露，德睿智藥與澳門大學、帝國理工學院合作開展的阿爾茨海默病藥物發現研究發表於《Nature Biomedical Engineering》。相關工作將AI篩選與實驗驗證結合，發現具有進一步研究價值的小分子，體現了公司在複雜疾病藥物發現方向上的前沿探索和研發能力。 這些項目所處階段不同，對公司價值的貢獻也需要分別觀察：MDR-001承擔現階段臨床開發與商業化準備的主要看點，其他管線和研究則為平台的延展能力及長期項目儲備提供支持。隨著更多項目取得可驗證的進展，外界才能進一步判斷公司的研發能力能否穩定複製。 從這一視角看，近期商業化合作為重新認識德睿智藥提供了契機。核心產品進入關鍵臨床階段，合作夥伴提前參與商業化準備，融資為持續研發提供支持，多方向布局則保留了後續成長的可能性。幾項進展相互聯繫，使公司的發展路徑更容易被資本市場理解。 MDR-001目前仍處於臨床開發階段，尚未獲批上市，其後續價值實現取決於臨床結果、監管審批及商業執行。但已經取得的業務進展，使德睿智藥具備了更具體的觀察基礎。對於關注AI與創新藥交匯機會的投資人而言，公司值得持續跟蹤的核心，在於能否將已經形成的研發能力，逐步轉化為更多可驗證的藥物資產與商業成果。
- 从Ⅲ期临床到商业化合作 德睿智药的AI制药价值逐步显现香港, 2026年10月9日 - (亚太商讯) - AI制药进入准商业化阶段，德睿智药迎来关键业务进展 AI究竟能为新药研发创造多大价值？对于关注这一领域的投资人而言，答案需要在具体的药物和业务进展中寻找。研发平台能否持续产出候选药物，核心产品能否取得临床进展，以及研发成果能否获得产业合作伙伴认可，共同构成了判断一家AI制药企业成长潜力的重要依据。 杭州德睿智药科技有限公司（MindRank，以下简称“德睿智药”）近期披露的商业化合作，为观察这一问题提供了新的窗口。 2026年9月28日，德睿智药宣布，与三生制药（01530.HK）旗下三生蔓迪及万晟医药，就其自主研发的AI设计口服小分子GLP-1受体激动剂MDR-001达成独家商业化合作，覆盖中国内地、香港及澳门，潜在总交易金额最高可达人民币17.5亿元，并可获高比例销售分成。该产品目前正在中国开展针对成人肥胖或超重人群的Ⅲ期关键临床研究。 对于德睿智药这家临床阶段AI Native新药研发科技公司而言，此次合作进一步衔接了新药研发与商业化布局，为核心产品未来获批后的市场推广奠定基础，也让AI驱动的研发成果向商业价值转化的路径更加清晰。在核心产品推进关键临床研究的同时，德睿智药开始为未来获批后的市场推广和渠道覆盖作准备，使产品开发路径进一步延伸至商业化环节。 根据协议安排，三生蔓迪及万晟医药将承接MDR-001上市后的全渠道独家综合与经销服务；德睿智药保留产品知识产权的全部权利、权属和权益，继续负责临床开发、注册申报与生产供应。交易包括最高1.5亿元合作权付款，以及达到约定条件后最高16亿元的特许权使用付款，以及高比例销售分成。 从业务模式来看，这一安排体现出明确的分工：德睿智药持续投入研发及产品开发，合作方负责约定区域内、产品获批上市后的全渠道独家综合与经销服务。对于需要长期投入的创新药业务，这种协同有望帮助德睿智药在保留核心资产权益的同时，借助合作方的商业运营能力衔接上市准备，并将自身资源集中于核心能力建设。 合作方愿意围绕一款在研产品作出商业化安排，也为外界评估其潜在产业价值提供了新的参考。临床数据回答产品是否值得继续开发，商业合作则进一步回答产业伙伴是否愿意参与其后续发展。两者相互衔接，使德睿智药的成长逻辑更加具体。 核心产品迈入Ⅲ期，让AI研发能力有了更清晰的观察依据 支撑此次合作的核心资产，是持续取得研发进展的MDR-001。 2026年2月，德睿智药宣布，MDR-001的Ⅲ期临床研究MOBILE完成首例受试者给药。根据公司披露，该研究采用多中心、随机、双盲、安慰剂对照设计，计划在中国约50家临床中心纳入约750名受试者，进一步评价产品的长期有效性与安全性。 这意味着，评价德睿智药AI研发能力的依据，已经延伸至较大规模的后期临床研究。对于投资人而言，核心管线进入Ⅲ期，使后续观察重点更加明确：长期疗效能否得到进一步验证，安全性和耐受性表现能否延续，以及产品能否形成具有实际临床意义的竞争力。 此前披露的Ⅱb期研究为后续开发提供了支持。在这项纳入317名成人肥胖或超重受试者的研究中，MDR-001各剂量组治疗24周后平均体重较基线下降8.2%至10.3%，安慰剂组下降2.5%；因治疗期间出现的不良事件而终止治疗的比例为0.8%。研究中常见的不良事件主要为胃肠道症状，多为轻至中度。上述结果仍需通过后续研究进一步验证。 对于体重管理药物，产品价值需要综合考虑减重效果、长期安全性、耐受性和使用便利性。相较于当前主流的注射类多肽GLP-1药物，MDR-001作为口服小分子制剂，可显著提升患者用药依从性，规模化制备成本远低于多肽类药物，将极具市场潜力和商业价值。这为其后续产品定位提供了一个值得关注的方向；而能否将这一特点转化为实际竞争优势，则需要持续积累临床证据。 在产品进展之外，研发效率也是理解德睿智药的重要角度。 据公司披露，MDR-001从项目启动到确定临床前候选化合物（PCC）仅用8个月，期间实际合成约80个小分子；从项目启动至获得美国新药临床试验许可用时19个月，约4.5年推进至中国Ⅲ期临床。公司2026年7月发布的融资消息进一步披露，从立项至中国Ⅲ期临床启动，项目累计直接研发投入约2,300万美元。 这些时间与投入数据，为理解德睿智药如何组织新药研发提供了更具体的讨论基础。对于新药研发企业而言，研发周期与资金投入直接关系到企业能够推进多少项目、承担多长时间的开发，以及如何安排后续资源。AI的商业意义，也需要放在这些真实的研发约束中衡量。 作为德睿智药AI新药研发体系的核心实践，MDR-001已经提供了一条可追踪的开发路径：从分子设计到临床研究，再到商业化合作，平台能力开始通过实际业务成果接受检验。这比单纯介绍算法或模型参数，更有助于资本市场理解公司的技术价值。 从核心管线到平台延展，长期成长空间取决于持续产出能力 MDR-001决定了德睿智药现阶段最重要的业务看点，而公司的长期成长空间，还取决于能否持续开发出新的药物资产。 德睿智药披露的全链路AI制药引擎MAP（Molecule Arts Platform），将生物学、化学、计算、实验验证与临床学习纳入统一新药研发体系。2026年7月，公司宣布分阶段完成累计5,200万美元B轮融资，资金将用于继续推进平台建设及临床、临床前管线开发。2026年9月，公司正式发布生命科学基座模型体系Intera (Intelligence Era)，并公布InteraFold系列首个模型InteraFold-Chem技术报告。 从经营角度看，平台建设与管线推进具有相互促进的潜力：研发项目为平台带来真实问题和实验反馈，平台迭代则服务于后续项目的发现与优化。其价值最终需要体现为持续产出能力——能否在不同靶点和疾病领域推进更多具备开发价值的分子，并逐步形成多项资产支撑的业务结构。 德睿智药已在代谢疾病之外展开布局。公司于2025年3月披露，口服WEE1及YES1双靶点抑制剂MRANK-106获得美国FDA的新药临床试验许可，拟用于开展肿瘤领域的临床研究。这一进展为观察其AI平台在不同研发方向上的适用性提供了另一个案例，相关产品潜力仍需后续临床验证。 在更早期的研究方面，公司于2026年4月披露，德睿智药与澳门大学、帝国理工学院合作开展的阿尔茨海默病药物发现研究发表于《Nature Biomedical Engineering》。相关工作将AI筛选与实验验证结合，发现具有进一步研究价值的小分子，体现了公司在复杂疾病药物发现方向上的前沿探索和研发能力。 这些项目所处阶段不同，对公司价值的贡献也需要分别观察：MDR-001承担现阶段临床开发与商业化准备的主要看点，其他管线和研究则为平台的延展能力及长期项目储备提供支持。随着更多项目取得可验证的进展，外界才能进一步判断公司的研发能力能否稳定复制。 从这一视角看，近期商业化合作为重新认识德睿智药提供了契机。核心产品进入关键临床阶段，合作伙伴提前参与商业化准备，融资为持续研发提供支持，多方向布局则保留了后续成长的可能性。几项进展相互联系，使公司的发展路径更容易被资本市场理解。 MDR-001目前仍处于临床开发阶段，尚未获批上市，其后续价值实现取决于临床结果、监管审批及商业执行。但已经取得的业务进展，使德睿智药具备了更具体的观察基础。对于关注AI与创新药交汇机会的投资人而言，公司值得持续跟踪的核心，在于能否将已经形成的研发能力，逐步转化为更多可验证的药物资产与商业成果。 Copyright 2026 亚太商讯. All rights reserved. www.acnnewswire.com
- Antengene Corporation LimitedAntengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- Everest MedicinesEverest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical DevelopmentLakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines Appointments support continued advancement of Everest's mRNA...
- Massachusetts Nurses AssociationMNA: Brigham Nurses Seek Compromise to Avert Strike While Protecting Patient Care Quality; MGB Makes Minimal Movement and Ends TalksNurses made substantial changes in their proposals to reach a fair contract; Mass General Brigham made $2.3 billion in profits last year and paid its CEO $9.2 million — Brigham and Women's Hospital (BWH) nurses entered negotiations on Thursday, October 8...
- Retension Pharmaceuticals Announces Pricing of Initial Public OfferingRetension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the pricing of its upsized initial public offering of 3,750,000 shares of its common stock at an initial public offering price of $12.00 per share. The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million. All shares of common stock are being offered by Retension. Retension has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on or about October 13, 2026, subject to the satisfaction of customary closing conditions. The shares are expected to begin trading on October 9, 2026 on the Nasdaq Capital Market under the ticker symbol “RTSN.”
- The Inner CircleThe Inner Circle acknowledges Dr. Reuben Azad as a Pinnacle Lifetime Member Inner Circle of ExcellenceProminently featured in The Inner Circle, Dr. Reuben Azad, MD, FACC is acknowledged as a Pinnacle Lifetime Member for his contributions to cardiology, cardiovascular disease prevention, and patient centered healthcare. Dr. Reuben Azad is a...
- MedStar HealthMedStar Health Introduces New Airbus H145 D3 Helicopter to Expand Critical Care Capabilities Across the RegionCompanies: AirbusMedSTAR Transport, MedStar Health's critical care transport program, is introducing a new Airbus H145 D3 helicopter to strengthen its ability to transport critically ill and injured patients across the Washington, D.C., and Maryland region. Only...
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- Levi & Korsinsky, LLPSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)Levi & Korsinsky announces that it has commenced an investigation of Orthofix Medical Inc. (NASDAQ: OFIX) concerning possible breaches of fiduciary duties. If you are a current shareholder of OFIX, you can request additional information here:...